#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0097] FIG. 24 shows the normal Raman spectra of the some of the primary neurotransmitters, dopamine (DA), serotonin (5-HT), and norepinephrine (NE).
1-1	0-1	[	_	_	
1-2	1-5	0097	_	_	
1-3	5-6	]	_	_	
1-4	7-10	FIG	_	_	
1-5	10-11	.	_	_	
1-6	12-14	24	_	_	
1-7	15-20	shows	_	_	
1-8	21-24	the	_	_	
1-9	25-31	normal	_	_	
1-10	32-37	Raman	_	_	
1-11	38-45	spectra	_	_	
1-12	46-48	of	_	_	
1-13	49-52	the	_	_	
1-14	53-57	some	_	_	
1-15	58-60	of	_	_	
1-16	61-64	the	_	_	
1-17	65-72	primary	_	_	
1-18	73-90	neurotransmitters	_	_	
1-19	90-91	,	_	_	
1-20	92-100	dopamine	_	_	
1-21	101-102	(	_	_	
1-22	102-104	DA	_	_	
1-23	104-105	)	_	_	
1-24	105-106	,	_	_	
1-25	107-116	serotonin	_	_	
1-26	117-118	(	_	_	
1-27	118-119	5	_	_	
1-28	119-120	-	_	_	
1-29	120-122	HT	_	_	
1-30	122-123	)	_	_	
1-31	123-124	,	_	_	
1-32	125-128	and	_	_	
1-33	129-143	norepinephrine	_	_	
1-34	144-145	(	_	_	
1-35	145-147	NE	_	_	
1-36	147-148	)	_	_	
1-37	148-149	.	_	_	

#Text=Most evident are the distinguishing peaks in each of the compounds.
2-1	150-154	Most	_	_	
2-2	155-162	evident	_	_	
2-3	163-166	are	_	_	
2-4	167-170	the	_	_	
2-5	171-185	distinguishing	_	_	
2-6	186-191	peaks	_	_	
2-7	192-194	in	_	_	
2-8	195-199	each	_	_	
2-9	200-202	of	_	_	
2-10	203-206	the	_	_	
2-11	207-216	compounds	_	_	
2-12	216-217	.	_	_	

#Text=When these same compounds are studied with SERS, a significant increase in sensitivity is observed, but similar distinguishing features are found.
3-1	218-222	When	_	_	
3-2	223-228	these	_	_	
3-3	229-233	same	_	_	
3-4	234-243	compounds	_	_	
3-5	244-247	are	_	_	
3-6	248-255	studied	_	_	
3-7	256-260	with	_	_	
3-8	261-265	SERS	_	_	
3-9	265-266	,	_	_	
3-10	267-268	a	_	_	
3-11	269-280	significant	_	_	
3-12	281-289	increase	_	_	
3-13	290-292	in	_	_	
3-14	293-304	sensitivity	_	_	
3-15	305-307	is	_	_	
3-16	308-316	observed	_	_	
3-17	316-317	,	_	_	
3-18	318-321	but	_	_	
3-19	322-329	similar	_	_	
3-20	330-344	distinguishing	_	_	
3-21	345-353	features	_	_	
3-22	354-357	are	_	_	
3-23	358-363	found	_	_	
3-24	363-364	.	_	_	

#Text=The detection of NTs using silver electrodes and gold colloids has been demonstrated.
4-1	365-368	The	_	_	
4-2	369-378	detection	_	_	
4-3	379-381	of	_	_	
4-4	382-385	NTs	_	_	
4-5	386-391	using	_	_	
4-6	392-398	silver	_	_	
4-7	399-409	electrodes	_	_	
4-8	410-413	and	_	_	
4-9	414-418	gold	_	_	
4-10	419-427	colloids	_	_	
4-11	428-431	has	_	_	
4-12	432-436	been	_	_	
4-13	437-449	demonstrated	_	_	
4-14	449-450	.	_	_	

#Text=See Morris, M.
5-1	451-454	See	_	_	
5-2	455-461	Morris	_	_	
5-3	461-462	,	_	_	
5-4	463-464	M	_	_	
5-5	464-465	.	_	_	

#Text=D.; McGlashen, M.
6-1	466-467	D	_	_	
6-2	467-468	.	_	_	
6-3	468-469	;	_	_	
6-4	470-479	McGlashen	_	_	
6-5	479-480	,	_	_	
6-6	481-482	M	_	_	
6-7	482-483	.	_	_	

#Text=L.; Davis, K.
7-1	484-485	L	_	_	
7-2	485-486	.	_	_	
7-3	486-487	;	_	_	
7-4	488-493	Davis	_	_	
7-5	493-494	,	_	_	
7-6	495-496	K	_	_	
7-7	496-497	.	_	_	

#Text=L., Surface-enhanced Raman (SERS) probes of neurotransmitters.
8-1	498-499	L	_	_	
8-2	499-500	.	_	_	
8-3	500-501	,	_	_	
8-4	502-518	Surface-enhanced	_	_	
8-5	519-524	Raman	_	_	
8-6	525-526	(	_	_	
8-7	526-530	SERS	_	_	
8-8	530-531	)	_	_	
8-9	532-538	probes	_	_	
8-10	539-541	of	_	_	
8-11	542-559	neurotransmitters	_	_	
8-12	559-560	.	_	_	

#Text=Proceedings of SPIE--The International Societyfor Optical Engineering 1990, 1201, (Proc.
9-1	561-572	Proceedings	_	_	
9-2	573-575	of	_	_	
9-3	576-580	SPIE	_	_	
9-4	580-581	-	_	_	
9-5	581-582	-	_	_	
9-6	582-585	The	_	_	
9-7	586-599	International	_	_	
9-8	600-610	Societyfor	_	_	
9-9	611-618	Optical	_	_	
9-10	619-630	Engineering	_	_	
9-11	631-635	1990	_	_	
9-12	635-636	,	_	_	
9-13	637-641	1201	_	_	
9-14	641-642	,	_	_	
9-15	643-644	(	_	_	
9-16	644-648	Proc	_	_	
9-17	648-649	.	_	_	

#Text=Opt.
10-1	650-653	Opt	_	_	
10-2	653-654	.	_	_	

#Text=Fibers Med. 5, 1990), 447-50; Kneipp, K.; Wang, Y.; Dasari, R.
11-1	655-661	Fibers	_	_	
11-2	662-665	Med	_	_	
11-3	665-666	.	_	_	
11-4	667-668	5	_	_	
11-5	668-669	,	_	_	
11-6	670-674	1990	_	_	
11-7	674-675	)	_	_	
11-8	675-676	,	_	_	
11-9	677-680	447	_	_	
11-10	680-681	-	_	_	
11-11	681-683	50	_	_	
11-12	683-684	;	_	_	
11-13	685-691	Kneipp	_	_	
11-14	691-692	,	_	_	
11-15	693-694	K	_	_	
11-16	694-695	.	_	_	
11-17	695-696	;	_	_	
11-18	697-701	Wang	_	_	
11-19	701-702	,	_	_	
11-20	703-704	Y	_	_	
11-21	704-705	.	_	_	
11-22	705-706	;	_	_	
11-23	707-713	Dasari	_	_	
11-24	713-714	,	_	_	
11-25	715-716	R	_	_	
11-26	716-717	.	_	_	

#Text=R.; Feld, M.
12-1	718-719	R	_	_	
12-2	719-720	.	_	_	
12-3	720-721	;	_	_	
12-4	722-726	Feld	_	_	
12-5	726-727	,	_	_	
12-6	728-729	M	_	_	
12-7	729-730	.	_	_	

#Text=S., Near-infrared Surface-Enhanced Raman Scattering (NIR-SERS) of Neurotransmitters in Colloidal Silver Solutions.
13-1	731-732	S	_	_	
13-2	732-733	.	_	_	
13-3	733-734	,	_	_	
13-4	735-748	Near-infrared	_	_	
13-5	749-765	Surface-Enhanced	_	_	
13-6	766-771	Raman	_	_	
13-7	772-782	Scattering	_	_	
13-8	783-784	(	_	_	
13-9	784-792	NIR-SERS	_	_	
13-10	792-793	)	_	_	
13-11	794-796	of	_	_	
13-12	797-814	Neurotransmitters	_	_	
13-13	815-817	in	_	_	
13-14	818-827	Colloidal	_	_	
13-15	828-834	Silver	_	_	
13-16	835-844	Solutions	_	_	
13-17	844-845	.	_	_	

#Text=Spectrochimica Acta 1995, 51A, (3), 481-487.
14-1	846-860	Spectrochimica	_	_	
14-2	861-865	Acta	_	_	
14-3	866-870	1995	_	_	
14-4	870-871	,	_	_	
14-5	872-875	51A	_	_	
14-6	875-876	,	_	_	
14-7	877-878	(	_	_	
14-8	878-879	3	_	_	
14-9	879-880	)	_	_	
14-10	880-881	,	_	_	
14-11	882-885	481	_	_	
14-12	885-886	-	_	_	
14-13	886-889	487	_	_	
14-14	889-890	.	_	_	

#Text=However, a problem when using electrode surfaces is that they can foul up easily and provide irreproducible results.
15-1	891-898	However	_	_	
15-2	898-899	,	_	_	
15-3	900-901	a	_	_	
15-4	902-909	problem	_	_	
15-5	910-914	when	_	_	
15-6	915-920	using	_	_	
15-7	921-930	electrode	_	_	
15-8	931-939	surfaces	_	_	
15-9	940-942	is	_	_	
15-10	943-947	that	_	_	
15-11	948-952	they	_	_	
15-12	953-956	can	_	_	
15-13	957-961	foul	_	_	
15-14	962-964	up	_	_	
15-15	965-971	easily	_	_	
15-16	972-975	and	_	_	
15-17	976-983	provide	_	_	
15-18	984-998	irreproducible	_	_	
15-19	999-1006	results	_	_	
15-20	1006-1007	.	_	_	

#Text=Gold colloids constituted an advance toward an effective assay, but detection levels were above metabolic levels in the dialysate from rat brains.
#Text=[0098] According to one aspect of the present invention, an experimental approach uses designer coatings that have chemical specificity toward neurotransmitters.
16-1	1008-1012	Gold	_	_	
16-2	1013-1021	colloids	_	_	
16-3	1022-1033	constituted	_	_	
16-4	1034-1036	an	_	_	
16-5	1037-1044	advance	_	_	
16-6	1045-1051	toward	_	_	
16-7	1052-1054	an	_	_	
16-8	1055-1064	effective	_	_	
16-9	1065-1070	assay	_	_	
16-10	1070-1071	,	_	_	
16-11	1072-1075	but	_	_	
16-12	1076-1085	detection	_	_	
16-13	1086-1092	levels	_	_	
16-14	1093-1097	were	_	_	
16-15	1098-1103	above	_	_	
16-16	1104-1113	metabolic	_	_	
16-17	1114-1120	levels	_	_	
16-18	1121-1123	in	_	_	
16-19	1124-1127	the	_	_	
16-20	1128-1137	dialysate	_	_	
16-21	1138-1142	from	_	_	
16-22	1143-1146	rat	_	_	
16-23	1147-1153	brains	_	_	
16-24	1153-1154	.	_	_	
16-25	1155-1156	[	_	_	
16-26	1156-1160	0098	_	_	
16-27	1160-1161	]	_	_	
16-28	1162-1171	According	_	_	
16-29	1172-1174	to	_	_	
16-30	1175-1178	one	_	_	
16-31	1179-1185	aspect	_	_	
16-32	1186-1188	of	_	_	
16-33	1189-1192	the	_	_	
16-34	1193-1200	present	_	_	
16-35	1201-1210	invention	_	_	
16-36	1210-1211	,	_	_	
16-37	1212-1214	an	_	_	
16-38	1215-1227	experimental	_	_	
16-39	1228-1236	approach	_	_	
16-40	1237-1241	uses	_	_	
16-41	1242-1250	designer	_	_	
16-42	1251-1259	coatings	_	_	
16-43	1260-1264	that	_	_	
16-44	1265-1269	have	_	_	
16-45	1270-1278	chemical	_	_	
16-46	1279-1290	specificity	_	_	
16-47	1291-1297	toward	_	_	
16-48	1298-1315	neurotransmitters	_	_	
16-49	1315-1316	.	_	_	

#Text=The coatings are designed with two reactive sites: one for the neurotransmitter and the other specific to a spectral enhancement particle surface.
17-1	1317-1320	The	_	_	
17-2	1321-1329	coatings	_	_	
17-3	1330-1333	are	_	_	
17-4	1334-1342	designed	_	_	
17-5	1343-1347	with	_	_	
17-6	1348-1351	two	_	_	
17-7	1352-1360	reactive	_	_	
17-8	1361-1366	sites	_	_	
17-9	1366-1367	:	_	_	
17-10	1368-1371	one	_	_	
17-11	1372-1375	for	_	_	
17-12	1376-1379	the	_	_	
17-13	1380-1396	neurotransmitter	_	_	
17-14	1397-1400	and	_	_	
17-15	1401-1404	the	_	_	
17-16	1405-1410	other	_	_	
17-17	1411-1419	specific	_	_	
17-18	1420-1422	to	_	_	
17-19	1423-1424	a	_	_	
17-20	1425-1433	spectral	_	_	
17-21	1434-1445	enhancement	_	_	
17-22	1446-1454	particle	_	_	
17-23	1455-1462	surface	_	_	
17-24	1462-1463	.	_	_	

#Text=This technique has the advantages of selectivity due to the reactivity of the coating and the structural specificity of Raman spectroscopy; and high sensitivity due to the concentration of neurotransmitters at the spectral enhancement particle surface and the strong amplification of Raman scattering at spectral enhancement particle surfaces arising from the Surface Enhanced Raman Scattering (SERS) effect.
#Text=[0099] The present invention uses the properties of the paramagnetic particles to separate the desired neurotransmitter adducts on silver spectral enhancement particles from the complex matrices that are dealt with in pharmacological research involving the detection of serotonin during the study of atypical antipsychotic drugs such as clozapine and haloperidol.
18-1	1464-1468	This	_	_	
18-2	1469-1478	technique	_	_	
18-3	1479-1482	has	_	_	
18-4	1483-1486	the	_	_	
18-5	1487-1497	advantages	_	_	
18-6	1498-1500	of	_	_	
18-7	1501-1512	selectivity	_	_	
18-8	1513-1516	due	_	_	
18-9	1517-1519	to	_	_	
18-10	1520-1523	the	_	_	
18-11	1524-1534	reactivity	_	_	
18-12	1535-1537	of	_	_	
18-13	1538-1541	the	_	_	
18-14	1542-1549	coating	_	_	
18-15	1550-1553	and	_	_	
18-16	1554-1557	the	_	_	
18-17	1558-1568	structural	_	_	
18-18	1569-1580	specificity	_	_	
18-19	1581-1583	of	_	_	
18-20	1584-1589	Raman	_	_	
18-21	1590-1602	spectroscopy	_	_	
18-22	1602-1603	;	_	_	
18-23	1604-1607	and	_	_	
18-24	1608-1612	high	_	_	
18-25	1613-1624	sensitivity	_	_	
18-26	1625-1628	due	_	_	
18-27	1629-1631	to	_	_	
18-28	1632-1635	the	_	_	
18-29	1636-1649	concentration	_	_	
18-30	1650-1652	of	_	_	
18-31	1653-1670	neurotransmitters	_	_	
18-32	1671-1673	at	_	_	
18-33	1674-1677	the	_	_	
18-34	1678-1686	spectral	_	_	
18-35	1687-1698	enhancement	_	_	
18-36	1699-1707	particle	_	_	
18-37	1708-1715	surface	_	_	
18-38	1716-1719	and	_	_	
18-39	1720-1723	the	_	_	
18-40	1724-1730	strong	_	_	
18-41	1731-1744	amplification	_	_	
18-42	1745-1747	of	_	_	
18-43	1748-1753	Raman	_	_	
18-44	1754-1764	scattering	_	_	
18-45	1765-1767	at	_	_	
18-46	1768-1776	spectral	_	_	
18-47	1777-1788	enhancement	_	_	
18-48	1789-1797	particle	_	_	
18-49	1798-1806	surfaces	_	_	
18-50	1807-1814	arising	_	_	
18-51	1815-1819	from	_	_	
18-52	1820-1823	the	_	_	
18-53	1824-1831	Surface	_	_	
18-54	1832-1840	Enhanced	_	_	
18-55	1841-1846	Raman	_	_	
18-56	1847-1857	Scattering	_	_	
18-57	1858-1859	(	_	_	
18-58	1859-1863	SERS	_	_	
18-59	1863-1864	)	_	_	
18-60	1865-1871	effect	_	_	
18-61	1871-1872	.	_	_	
18-62	1873-1874	[	_	_	
18-63	1874-1878	0099	_	_	
18-64	1878-1879	]	_	_	
18-65	1880-1883	The	_	_	
18-66	1884-1891	present	_	_	
18-67	1892-1901	invention	_	_	
18-68	1902-1906	uses	*[1]	25-3[2_1]	
18-69	1907-1910	the	*[1]	_	
18-70	1911-1921	properties	*[1]	_	
18-71	1922-1924	of	*[1]	_	
18-72	1925-1928	the	*[1]	_	
18-73	1929-1941	paramagnetic	*[1]	_	
18-74	1942-1951	particles	*[1]	_	
18-75	1952-1954	to	*[1]	_	
18-76	1955-1963	separate	*[1]	_	
18-77	1964-1967	the	*[1]	_	
18-78	1968-1975	desired	*[1]	_	
18-79	1976-1992	neurotransmitter	*[1]	_	
18-80	1993-2000	adducts	*[1]	_	
18-81	2001-2003	on	*[1]	_	
18-82	2004-2010	silver	*[1]	_	
18-83	2011-2019	spectral	*[1]	_	
18-84	2020-2031	enhancement	*[1]	_	
18-85	2032-2041	particles	*[1]	_	
18-86	2042-2046	from	*[1]	_	
18-87	2047-2050	the	*[1]	_	
18-88	2051-2058	complex	*[1]	_	
18-89	2059-2067	matrices	*[1]	_	
18-90	2068-2072	that	_	_	
18-91	2073-2076	are	_	_	
18-92	2077-2082	dealt	_	_	
18-93	2083-2087	with	_	_	
18-94	2088-2090	in	_	_	
18-95	2091-2106	pharmacological	_	_	
18-96	2107-2115	research	_	_	
18-97	2116-2125	involving	_	_	
18-98	2126-2129	the	_	_	
18-99	2130-2139	detection	_	_	
18-100	2140-2142	of	_	_	
18-101	2143-2152	serotonin	_	_	
18-102	2153-2159	during	_	_	
18-103	2160-2163	the	_	_	
18-104	2164-2169	study	_	_	
18-105	2170-2172	of	_	_	
18-106	2173-2181	atypical	_	_	
18-107	2182-2195	antipsychotic	_	_	
18-108	2196-2201	drugs	_	_	
18-109	2202-2206	such	_	_	
18-110	2207-2209	as	_	_	
18-111	2210-2219	clozapine	_	_	
18-112	2220-2223	and	_	_	
18-113	2224-2235	haloperidol	_	_	
18-114	2235-2236	.	_	_	

#Text=The chemical structure of dopamine, serotonin, norepinephrine all have a common chemical feature; they all contain electron-rich sites on their aromatic rings.
19-1	2237-2240	The	_	_	
19-2	2241-2249	chemical	_	_	
19-3	2250-2259	structure	_	_	
19-4	2260-2262	of	_	_	
19-5	2263-2271	dopamine	_	_	
19-6	2271-2272	,	_	_	
19-7	2273-2282	serotonin	_	_	
19-8	2282-2283	,	_	_	
19-9	2284-2298	norepinephrine	_	_	
19-10	2299-2302	all	_	_	
19-11	2303-2307	have	_	_	
19-12	2308-2309	a	_	_	
19-13	2310-2316	common	_	_	
19-14	2317-2325	chemical	_	_	
19-15	2326-2333	feature	_	_	
19-16	2333-2334	;	_	_	
19-17	2335-2339	they	_	_	
19-18	2340-2343	all	_	_	
19-19	2344-2351	contain	_	_	
19-20	2352-2365	electron-rich	_	_	
19-21	2366-2371	sites	_	_	
19-22	2372-2374	on	_	_	
19-23	2375-2380	their	_	_	
19-24	2381-2389	aromatic	_	_	
19-25	2390-2395	rings	_	_	
19-26	2395-2396	.	_	_	

#Text=This makes these compounds susceptible to reaction with diazoniums to form azo adducts.
20-1	2397-2401	This	_	_	
20-2	2402-2407	makes	_	_	
20-3	2408-2413	these	_	_	
20-4	2414-2423	compounds	_	_	
20-5	2424-2435	susceptible	_	_	
20-6	2436-2438	to	_	_	
20-7	2439-2447	reaction	_	_	
20-8	2448-2452	with	_	_	
20-9	2453-2463	diazoniums	_	_	
20-10	2464-2466	to	_	_	
20-11	2467-2471	form	_	_	
20-12	2472-2475	azo	_	_	
20-13	2476-2483	adducts	_	_	
20-14	2483-2484	.	_	_	

#Text=Azo compounds make up a large number of popular dyes.
21-1	2485-2488	Azo	_	_	
21-2	2489-2498	compounds	_	_	
21-3	2499-2503	make	_	_	
21-4	2504-2506	up	_	_	
21-5	2507-2508	a	_	_	
21-6	2509-2514	large	_	_	
21-7	2515-2521	number	_	_	
21-8	2522-2524	of	_	_	
21-9	2525-2532	popular	_	_	
21-10	2533-2537	dyes	_	_	
21-11	2537-2538	.	_	_	

#Text=The azo bridge contains n-.pi.* electronic transitions that provide moderate resonance Raman scattering.
22-1	2539-2542	The	_	_	
22-2	2543-2546	azo	_	_	
22-3	2547-2553	bridge	_	_	
22-4	2554-2562	contains	_	_	
22-5	2563-2564	n	_	_	
22-6	2564-2565	-	_	_	
22-7	2565-2566	.	_	_	
22-8	2566-2568	pi	_	_	
22-9	2568-2569	.	_	_	
22-10	2569-2570	*	_	_	
22-11	2571-2581	electronic	_	_	
22-12	2582-2593	transitions	_	_	
22-13	2594-2598	that	_	_	
22-14	2599-2606	provide	_	_	
22-15	2607-2615	moderate	_	_	
22-16	2616-2625	resonance	_	_	
22-17	2626-2631	Raman	_	_	
22-18	2632-2642	scattering	_	_	
22-19	2642-2643	.	_	_	

#Text=The silver spectral enhancement particle provides an enhancement of approximately a factor of 10.sup.7.
23-1	2644-2647	The	_	_	
23-2	2648-2654	silver	_	_	
23-3	2655-2663	spectral	_	_	
23-4	2664-2675	enhancement	_	_	
23-5	2676-2684	particle	_	_	
23-6	2685-2693	provides	_	_	
23-7	2694-2696	an	_	_	
23-8	2697-2708	enhancement	_	_	
23-9	2709-2711	of	_	_	
23-10	2712-2725	approximately	_	_	
23-11	2726-2727	a	_	_	
23-12	2728-2734	factor	_	_	
23-13	2735-2737	of	_	_	
23-14	2738-2740	10	_	_	
23-15	2740-2741	.	_	_	
23-16	2741-2744	sup	_	_	
23-17	2744-2746	.7	_	_	
23-18	2746-2747	.	_	_	

#Text=The combination of enhancements produces subnanomolar detection limits.
24-1	2748-2751	The	_	_	
24-2	2752-2763	combination	_	_	
24-3	2764-2766	of	_	_	
24-4	2767-2779	enhancements	_	_	
24-5	2780-2788	produces	_	_	
24-6	2789-2801	subnanomolar	_	_	
24-7	2802-2811	detection	_	_	
24-8	2812-2818	limits	_	_	
24-9	2818-2819	.	_	_	

#Text=Moreover, this process is extremely rapid (approximately 30 seconds) whereas the standard method of high performance liquid chromatography (HPLC) separation and electrochemical detection takes much longer.
25-1	2820-2828	Moreover	_	_	
25-2	2828-2829	,	_	_	
25-3	2830-2834	this	*[2]	_	
25-4	2835-2842	process	*[2]	_	
25-5	2843-2845	is	_	_	
25-6	2846-2855	extremely	_	_	
25-7	2856-2861	rapid	_	_	
25-8	2862-2863	(	_	_	
25-9	2863-2876	approximately	_	_	
25-10	2877-2879	30	_	_	
25-11	2880-2887	seconds	_	_	
25-12	2887-2888	)	_	_	
25-13	2889-2896	whereas	_	_	
25-14	2897-2900	the	_	_	
25-15	2901-2909	standard	_	_	
25-16	2910-2916	method	_	_	
25-17	2917-2919	of	_	_	
25-18	2920-2924	high	_	_	
25-19	2925-2936	performance	_	_	
25-20	2937-2943	liquid	_	_	
25-21	2944-2958	chromatography	_	_	
25-22	2959-2960	(	_	_	
25-23	2960-2964	HPLC	_	_	
25-24	2964-2965	)	_	_	
25-25	2966-2976	separation	_	_	
25-26	2977-2980	and	_	_	
25-27	2981-2996	electrochemical	_	_	
25-28	2997-3006	detection	_	_	
25-29	3007-3012	takes	_	_	
25-30	3013-3017	much	_	_	
25-31	3018-3024	longer	_	_	
25-32	3024-3025	.	_	_	

#Text=The HPLC method alone requires approximately 30 minutes per assay.
#Text=[0100] The physical properties and synthetic methods for creating nanoscale paramagnetic particles are well established.
26-1	3026-3029	The	_	_	
26-2	3030-3034	HPLC	_	_	
26-3	3035-3041	method	_	_	
26-4	3042-3047	alone	_	_	
26-5	3048-3056	requires	_	_	
26-6	3057-3070	approximately	_	_	
26-7	3071-3073	30	_	_	
26-8	3074-3081	minutes	_	_	
26-9	3082-3085	per	_	_	
26-10	3086-3091	assay	_	_	
26-11	3091-3092	.	_	_	
26-12	3093-3094	[	_	_	
26-13	3094-3098	0100	_	_	
26-14	3098-3099	]	_	_	
26-15	3100-3103	The	_	_	
26-16	3104-3112	physical	_	_	
26-17	3113-3123	properties	_	_	
26-18	3124-3127	and	_	_	
26-19	3128-3137	synthetic	_	_	
26-20	3138-3145	methods	_	_	
26-21	3146-3149	for	_	_	
26-22	3150-3158	creating	_	_	
26-23	3159-3168	nanoscale	_	_	
26-24	3169-3181	paramagnetic	_	_	
26-25	3182-3191	particles	_	_	
26-26	3192-3195	are	_	_	
26-27	3196-3200	well	_	_	
26-28	3201-3212	established	_	_	
26-29	3212-3213	.	_	_	

#Text=The small paramagnetic particles have found wide application as separation facilitators in techniques such as immunoassays and a wide variety of biomedical applications.
27-1	3214-3217	The	_	_	
27-2	3218-3223	small	_	_	
27-3	3224-3236	paramagnetic	_	_	
27-4	3237-3246	particles	_	_	
27-5	3247-3251	have	_	_	
27-6	3252-3257	found	_	_	
27-7	3258-3262	wide	_	_	
27-8	3263-3274	application	_	_	
27-9	3275-3277	as	_	_	
27-10	3278-3288	separation	_	_	
27-11	3289-3301	facilitators	_	_	
27-12	3302-3304	in	_	_	
27-13	3305-3315	techniques	_	_	
27-14	3316-3320	such	_	_	
27-15	3321-3323	as	_	_	
27-16	3324-3336	immunoassays	_	_	
27-17	3337-3340	and	_	_	
27-18	3341-3342	a	_	_	
27-19	3343-3347	wide	_	_	
27-20	3348-3355	variety	_	_	
27-21	3356-3358	of	_	_	
27-22	3359-3369	biomedical	_	_	
27-23	3370-3382	applications	_	_	
27-24	3382-3383	.	_	_	

#Text=Paramagnetic particles are composed of materials with an unpaired electron.
28-1	3384-3396	Paramagnetic	_	_	
28-2	3397-3406	particles	_	_	
28-3	3407-3410	are	_	_	
28-4	3411-3419	composed	_	_	
28-5	3420-3422	of	_	_	
28-6	3423-3432	materials	_	_	
28-7	3433-3437	with	_	_	
28-8	3438-3440	an	_	_	
28-9	3441-3449	unpaired	_	_	
28-10	3450-3458	electron	_	_	
28-11	3458-3459	.	_	_	

#Text=For example, Fe.sup.3+ ions have 5 unpaired electrons.
29-1	3460-3463	For	_	_	
29-2	3464-3471	example	_	_	
29-3	3471-3472	,	_	_	
29-4	3473-3479	Fe.sup	_	_	
29-5	3479-3481	.3	_	_	
29-6	3481-3482	+	_	_	
29-7	3483-3487	ions	_	_	
29-8	3488-3492	have	_	_	
29-9	3493-3494	5	_	_	
29-10	3495-3503	unpaired	_	_	
29-11	3504-3513	electrons	_	_	
29-12	3513-3514	.	_	_	

#Text=This has a very strong paramagnetic reaction to a magnetic field.
30-1	3515-3519	This	_	_	
30-2	3520-3523	has	_	_	
30-3	3524-3525	a	_	_	
30-4	3526-3530	very	_	_	
30-5	3531-3537	strong	_	_	
30-6	3538-3550	paramagnetic	_	_	
30-7	3551-3559	reaction	_	_	
30-8	3560-3562	to	_	_	
30-9	3563-3564	a	_	_	
30-10	3565-3573	magnetic	_	_	
30-11	3574-3579	field	_	_	
30-12	3579-3580	.	_	_	

#Text=In general, assay material that reacts positively with a magnetic field and has a small susceptibility with a field is termed paramagnetic.
#Text=[0101] Silver particles can be kept at a very low concentration to keep the surface coverage of tethered serotonin high.
31-1	3581-3583	In	_	_	
31-2	3584-3591	general	_	_	
31-3	3591-3592	,	_	_	
31-4	3593-3598	assay	_	_	
31-5	3599-3607	material	_	_	
31-6	3608-3612	that	_	_	
31-7	3613-3619	reacts	_	_	
31-8	3620-3630	positively	_	_	
31-9	3631-3635	with	_	_	
31-10	3636-3637	a	_	_	
31-11	3638-3646	magnetic	_	_	
31-12	3647-3652	field	_	_	
31-13	3653-3656	and	_	_	
31-14	3657-3660	has	_	_	
31-15	3661-3662	a	_	_	
31-16	3663-3668	small	_	_	
31-17	3669-3683	susceptibility	_	_	
31-18	3684-3688	with	_	_	
31-19	3689-3690	a	_	_	
31-20	3691-3696	field	_	_	
31-21	3697-3699	is	_	_	
31-22	3700-3706	termed	_	_	
31-23	3707-3719	paramagnetic	_	_	
31-24	3719-3720	.	_	_	
31-25	3721-3722	[	_	_	
31-26	3722-3726	0101	_	_	
31-27	3726-3727	]	_	_	
31-28	3728-3734	Silver	_	_	
31-29	3735-3744	particles	_	_	
31-30	3745-3748	can	_	_	
31-31	3749-3751	be	_	_	
31-32	3752-3756	kept	_	_	
31-33	3757-3759	at	_	_	
31-34	3760-3761	a	_	_	
31-35	3762-3766	very	_	_	
31-36	3767-3770	low	_	_	
31-37	3771-3784	concentration	_	_	
31-38	3785-3787	to	_	_	
31-39	3788-3792	keep	_	_	
31-40	3793-3796	the	_	_	
31-41	3797-3804	surface	_	_	
31-42	3805-3813	coverage	_	_	
31-43	3814-3816	of	_	_	
31-44	3817-3825	tethered	_	_	
31-45	3826-3835	serotonin	_	_	
31-46	3836-3840	high	_	_	
31-47	3840-3841	.	_	_	

#Text=The coupling of the silver particles with paramagnetic particles permits a dilute solution of SERS active particles to be concentrated.
32-1	3842-3845	The	_	_	
32-2	3846-3854	coupling	_	_	
32-3	3855-3857	of	_	_	
32-4	3858-3861	the	_	_	
32-5	3862-3868	silver	_	_	
32-6	3869-3878	particles	_	_	
32-7	3879-3883	with	_	_	
32-8	3884-3896	paramagnetic	_	_	
32-9	3897-3906	particles	_	_	
32-10	3907-3914	permits	_	_	
32-11	3915-3916	a	_	_	
32-12	3917-3923	dilute	_	_	
32-13	3924-3932	solution	_	_	
32-14	3933-3935	of	_	_	
32-15	3936-3940	SERS	_	_	
32-16	3941-3947	active	_	_	
32-17	3948-3957	particles	_	_	
32-18	3958-3960	to	_	_	
32-19	3961-3963	be	_	_	
32-20	3964-3976	concentrated	_	_	
32-21	3976-3977	.	_	_	

#Text=This makes it possible to detect several orders of magnitude lower concentration of neurotransmitters than with the existing method.
33-1	3978-3982	This	_	_	
33-2	3983-3988	makes	_	_	
33-3	3989-3991	it	_	_	
33-4	3992-4000	possible	_	_	
33-5	4001-4003	to	_	_	
33-6	4004-4010	detect	_	_	
33-7	4011-4018	several	_	_	
33-8	4019-4025	orders	_	_	
33-9	4026-4028	of	_	_	
33-10	4029-4038	magnitude	_	_	
33-11	4039-4044	lower	_	_	
33-12	4045-4058	concentration	_	_	
33-13	4059-4061	of	_	_	
33-14	4062-4079	neurotransmitters	_	_	
33-15	4080-4084	than	_	_	
33-16	4085-4089	with	_	_	
33-17	4090-4093	the	_	_	
33-18	4094-4102	existing	_	_	
33-19	4103-4109	method	_	_	
33-20	4109-4110	.	_	_	

#Text=It has been shown that with a decrease of coverage there is an increase in the SERS enhancement.
34-1	4111-4113	It	_	_	
34-2	4114-4117	has	_	_	
34-3	4118-4122	been	_	_	
34-4	4123-4128	shown	_	_	
34-5	4129-4133	that	_	_	
34-6	4134-4138	with	_	_	
34-7	4139-4140	a	_	_	
34-8	4141-4149	decrease	_	_	
34-9	4150-4152	of	_	_	
34-10	4153-4161	coverage	_	_	
34-11	4162-4167	there	_	_	
34-12	4168-4170	is	_	_	
34-13	4171-4173	an	_	_	
34-14	4174-4182	increase	_	_	
34-15	4183-4185	in	_	_	
34-16	4186-4189	the	_	_	
34-17	4190-4194	SERS	_	_	
34-18	4195-4206	enhancement	_	_	
34-19	4206-4207	.	_	_	

#Text=In addition, the presence of excess silver nanoparticles that do not have analyte attached to the surface can adsorb and/or scatter the Raman photons.
35-1	4208-4210	In	_	_	
35-2	4211-4219	addition	_	_	
35-3	4219-4220	,	_	_	
35-4	4221-4224	the	_	_	
35-5	4225-4233	presence	_	_	
35-6	4234-4236	of	_	_	
35-7	4237-4243	excess	_	_	
35-8	4244-4250	silver	_	_	
35-9	4251-4264	nanoparticles	_	_	
35-10	4265-4269	that	_	_	
35-11	4270-4272	do	_	_	
35-12	4273-4276	not	_	_	
35-13	4277-4281	have	_	_	
35-14	4282-4289	analyte	_	_	
35-15	4290-4298	attached	_	_	
35-16	4299-4301	to	_	_	
35-17	4302-4305	the	_	_	
35-18	4306-4313	surface	_	_	
35-19	4314-4317	can	_	_	
35-20	4318-4324	adsorb	_	_	
35-21	4325-4328	and	_	_	
35-22	4328-4329	/	_	_	
35-23	4329-4331	or	_	_	
35-24	4332-4339	scatter	_	_	
35-25	4340-4343	the	_	_	
35-26	4344-4349	Raman	_	_	
35-27	4350-4357	photons	_	_	
35-28	4357-4358	.	_	_	

#Text=Selectively attaching analytes to the surface of silver nanoparticles allows for a high surface coverage at low analyte concentrations.
36-1	4359-4370	Selectively	_	_	
36-2	4371-4380	attaching	_	_	
36-3	4381-4389	analytes	_	_	
36-4	4390-4392	to	_	_	
36-5	4393-4396	the	_	_	
36-6	4397-4404	surface	_	_	
36-7	4405-4407	of	_	_	
36-8	4408-4414	silver	_	_	
36-9	4415-4428	nanoparticles	_	_	
36-10	4429-4435	allows	_	_	
36-11	4436-4439	for	_	_	
36-12	4440-4441	a	_	_	
36-13	4442-4446	high	_	_	
36-14	4447-4454	surface	_	_	
36-15	4455-4463	coverage	_	_	
36-16	4464-4466	at	_	_	
36-17	4467-4470	low	_	_	
36-18	4471-4478	analyte	_	_	
36-19	4479-4493	concentrations	_	_	
36-20	4493-4494	.	_	_	

#Text=Finally, the concentration of particles from a dilution solution/matrix will also allow for removing the SERS active portion of the assay from interferences such as ECF proteins.
37-1	4495-4502	Finally	_	_	
37-2	4502-4503	,	_	_	
37-3	4504-4507	the	_	_	
37-4	4508-4521	concentration	_	_	
37-5	4522-4524	of	_	_	
37-6	4525-4534	particles	_	_	
37-7	4535-4539	from	_	_	
37-8	4540-4541	a	_	_	
37-9	4542-4550	dilution	_	_	
37-10	4551-4559	solution	_	_	
37-11	4559-4560	/	_	_	
37-12	4560-4566	matrix	_	_	
37-13	4567-4571	will	_	_	
37-14	4572-4576	also	_	_	
37-15	4577-4582	allow	_	_	
37-16	4583-4586	for	_	_	
37-17	4587-4595	removing	_	_	
37-18	4596-4599	the	_	_	
37-19	4600-4604	SERS	_	_	
37-20	4605-4611	active	_	_	
37-21	4612-4619	portion	_	_	
37-22	4620-4622	of	_	_	
37-23	4623-4626	the	_	_	
37-24	4627-4632	assay	_	_	
37-25	4633-4637	from	_	_	
37-26	4638-4651	interferences	_	_	
37-27	4652-4656	such	_	_	
37-28	4657-4659	as	_	_	
37-29	4660-4663	ECF	_	_	
37-30	4664-4672	proteins	_	_	
37-31	4672-4673	.	_	_	

#Text=The chemical process of the present invention creates a neurotransmitter adduct that produces an additional resonant Raman enhancement of as much as an additional thousandfold improvement in sensitivity.
38-1	4674-4677	The	_	_	
38-2	4678-4686	chemical	_	_	
38-3	4687-4694	process	_	_	
38-4	4695-4697	of	_	_	
38-5	4698-4701	the	_	_	
38-6	4702-4709	present	_	_	
38-7	4710-4719	invention	_	_	
38-8	4720-4727	creates	_	_	
38-9	4728-4729	a	_	_	
38-10	4730-4746	neurotransmitter	_	_	
38-11	4747-4753	adduct	_	_	
38-12	4754-4758	that	_	_	
38-13	4759-4767	produces	_	_	
38-14	4768-4770	an	_	_	
38-15	4771-4781	additional	_	_	
38-16	4782-4790	resonant	_	_	
38-17	4791-4796	Raman	_	_	
38-18	4797-4808	enhancement	_	_	
38-19	4809-4811	of	_	_	
38-20	4812-4814	as	_	_	
38-21	4815-4819	much	_	_	
38-22	4820-4822	as	_	_	
38-23	4823-4825	an	_	_	
38-24	4826-4836	additional	_	_	
38-25	4837-4849	thousandfold	_	_	
38-26	4850-4861	improvement	_	_	
38-27	4862-4864	in	_	_	
38-28	4865-4876	sensitivity	_	_	
38-29	4876-4877	.	_	_	

#Text=Brownian motion of the nanoparticles mimics agitation and naturally mixes the reagents throughout the sample.
39-1	4878-4886	Brownian	_	_	
39-2	4887-4893	motion	_	_	
39-3	4894-4896	of	_	_	
39-4	4897-4900	the	_	_	
39-5	4901-4914	nanoparticles	_	_	
39-6	4915-4921	mimics	_	_	
39-7	4922-4931	agitation	_	_	
39-8	4932-4935	and	_	_	
39-9	4936-4945	naturally	_	_	
39-10	4946-4951	mixes	_	_	
39-11	4952-4955	the	_	_	
39-12	4956-4964	reagents	_	_	
39-13	4965-4975	throughout	_	_	
39-14	4976-4979	the	_	_	
39-15	4980-4986	sample	_	_	
39-16	4986-4987	.	_	_	

#Text=This combination of enhancements and comprehensive sample measurement has led to subnanomolar detection limits.
40-1	4988-4992	This	_	_	
40-2	4993-5004	combination	_	_	
40-3	5005-5007	of	_	_	
40-4	5008-5020	enhancements	_	_	
40-5	5021-5024	and	_	_	
40-6	5025-5038	comprehensive	_	_	
40-7	5039-5045	sample	_	_	
40-8	5046-5057	measurement	_	_	
40-9	5058-5061	has	_	_	
40-10	5062-5065	led	_	_	
40-11	5066-5068	to	_	_	
40-12	5069-5081	subnanomolar	_	_	
40-13	5082-5091	detection	_	_	
40-14	5092-5098	limits	_	_	
40-15	5098-5099	.	_	_	
